Directorate Changes | 05-Sep-2023 | 07:00 | RNS |
Final Report from Phase 1b PK/PD study | 15-Aug-2023 | 07:00 | RNS |
Rule 17 Disclosure | 03-Aug-2023 | 12:38 | RNS |
Return of rights to Sulforadex from Juvenescence | 02-Aug-2023 | 07:00 | RNS |
Result of AGM | 21-Jul-2023 | 12:02 | RNS |
Notice of AGM & Posting of Annual Report | 20-Jun-2023 | 13:59 | RNS |
Grant Success for Glioblastoma studies | 19-Jun-2023 | 07:00 | RNS |
Final Results | 07-Jun-2023 | 07:00 | RNS |
Notice of Results | 26-May-2023 | 11:00 | RNS |
Preliminary results from Phase 1b study | 22-Mar-2023 | 07:00 | RNS |
Price Monitoring Extension | 16-Mar-2023 | 14:00 | RNS |
Second Price Monitoring Extn | 16-Mar-2023 | 11:05 | RNS |
Price Monitoring Extension | 16-Mar-2023 | 11:00 | RNS |
No exposure to Silicon Valley Bank | 13-Mar-2023 | 07:00 | RNS |
Clinical trial update | 25-Jan-2023 | 07:00 | RNS |
Currency | UK Pounds |
Share Price | 1.95p |
Change Today | -0.15p |
% Change | -7.14 % |
52 Week High | 7.10 |
52 Week Low | 1.93 |
Volume | 417,085 |
Shares Issued | 274.89m |
Market Cap | £5.36m |
RiskGrade | 304 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth | ![]() |
---|
No dividends found |
Time | Volume / Share Price |
14:47 | 25,000 @ 2.00p |
14:02 | 30,000 @ 2.00p |
14:02 | 30,000 @ 2.00p |
14:02 | 967 @ 2.00p |
14:02 | 3,398 @ 2.00p |
You are here: research